Carisma Therapeutics Past Earnings Performance
Past criteria checks 0/6
Carisma Therapeutics's earnings have been declining at an average annual rate of -22.8%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 69.3% per year.
Key information
-22.8%
Earnings growth rate
67.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 69.3% |
| Return on equity | n/a |
| Net Margin | -314.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Carisma Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 20 | -64 | 24 | 0 |
| 30 Jun 24 | 21 | -73 | 25 | 0 |
| 31 Mar 24 | 15 | -81 | 25 | 0 |
| 31 Dec 23 | 15 | -87 | 30 | 0 |
| 30 Sep 23 | 14 | -83 | 23 | 0 |
| 30 Jun 23 | 13 | -80 | 20 | 0 |
| 31 Mar 23 | 12 | -75 | 17 | 0 |
| 31 Dec 22 | 10 | -61 | 9 | 0 |
| 30 Sep 22 | 6 | -57 | 11 | 0 |
| 30 Jun 22 | 4 | -49 | 9 | 0 |
| 31 Mar 22 | 1 | -43 | 8 | 0 |
| 31 Dec 21 | 0 | -41 | 6 | 0 |
Quality Earnings: W2J is currently unprofitable.
Growing Profit Margin: W2J is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: W2J is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
Accelerating Growth: Unable to compare W2J's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: W2J is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: W2J's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.